Cas:675617-95-5 2-ethyl-1,2,4-triazole-3-carbaldehyde manufacturer & supplier

We serve Chemical Name:2-ethyl-1,2,4-triazole-3-carbaldehyde CAS:675617-95-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-ethyl-1,2,4-triazole-3-carbaldehyde

Chemical Name:2-ethyl-1,2,4-triazole-3-carbaldehyde
CAS.NO:675617-95-5
Synonyms:1-Ethyl-1H-1,2,4-triazole-5-carbaldehyde
Molecular Formula:C5H7N3O
Molecular Weight:125.12900
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:277.4ºC at 760 mmHg
Density:1.24g/cm3
Index of Refraction:1.584
PSA:47.78000
Exact Mass:125.05900
LogP:0.11050

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1-Ethyl-1H-1,2,4-triazole-5-carbaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Ethyl-1H-1,2,4-triazole-5-carbaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Ethyl-1H-1,2,4-triazole-5-carbaldehyde Use and application,1-Ethyl-1H-1,2,4-triazole-5-carbaldehyde technical grade,usp/ep/jp grade.


Related News: The publication of the R&D People and Culture Strategy comes alongside the launch of the Innovation Strategy, which aims to make the UK a global hub for innovation and increase business investment in R&D. methyl 4-(2-chlorophenyl)-5-(ethoxycarbonyl)-2-methyl-6-({2-[4-(2-oxo-(6-hydroquinolyloxy))butanoylamino]ethoxy}methyl)-1,4-dihydropyridine-3-carboxylate manufacturers Along with Natural Biogenix were Symbiotec Pharmalab, Macleods Pharmaceutical, Optimus Drugs, Sudarshan Pharma, Saraca Laboratories, Emmennar Pharma, Hindys Lab, Aarti Speciality, Meghmani LLP and and Sadhana Nitro Chem. Benzamide, N,N-diethyl-3-[2-(3-methylphenoxy)ethoxy]- suppliers Conducted by Innovent in China, the CIBI321A101 trial is a Phase 1a open-label, multi-center study of the safety, tolerability and primary efficacy of IBI321 in patients with advanced solid tumors. Phase 1a of the study will evaluate dosing of IBI321 in a variety of solid tumors (ClinicalTrials.gov, NCT04911894). 6-phenyl-8H-pyrido[2,3-d]pyrimidine-5,7-dione vendor & factory.